REG - SkinBioTherapeutics - Issue of Equity and Total Voting Rights

SkinbiotherapeuticsAnnouncement

16/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241016:nRSP3220Ia&default-theme=true

RNS Number : 3220I  SkinBioTherapeutics PLC  16 October 2024

16 October 2024

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Company")

 

Issue of Equity and Total Voting Rights

 

SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life science
business focused on skin health, announces that it has issued, conditional on
admission, 2,349,624 new ordinary shares of 1 pence each in the capital of the
Company ("Ordinary Shares"), pursuant to the subscription agreement entered
into by the Company and an existing shareholder announced on 11 October 2024.

 

The new Ordinary Shares will rank pari passu with the existing Ordinary Shares
in issue and application has been made for the new Ordinary Shares to be
admitted to trading on the AIM Market of the London Stock Exchange
("Admission"). Admission is expected to occur, and dealings in the new
Ordinary Shares commence, at 8:00 a.m. on 17 October 2024.

 

Total Voting Rights

 

Following Admission, the Company will have 228,435,909 Ordinary Shares in
issue. This figure of 228,435,909 may be used by shareholders as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change of their interest in, the
Company under the FCA's Disclosure Guidance and Transparency Rules.

 

-Ends-

 

 

 

 

For more information please contact:

 

 SkinBioTherapeutics plc                            Tel: +44 (0) 191 495 7325

 Stuart J. Ashman, CEO

 Manprit Randhawa, CFO

 Cavendish Capital Markets Limited                  Tel: +44 (0) 20 7220 0500

 (Nominated Adviser & Broker)

 Giles Balleny, Dan Hodkinson (Corporate Finance)

 Charlie Combe (Broking)

 Dale Bellis, Tamar Cranford-Smith (Sales)

 Vigo Consulting (financial press)                  +44 (0) 20 7390 0231

 Rozi Morris                                        +44 (0) 7740 859 962

                                                    Skinbio@vigoconsulting.com (mailto:Skinbio@vigoconsulting.com)

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The
Company's proprietary platform technology, SkinBiotix(®), is based upon
discoveries made by the translational dermatology team at the University of
Manchester.

The Company is targeting a number of skin healthcare sectors, the most
advanced of which are cosmetic skincare and food supplements to modulate the
immune system by harnessing the gut-skin axis. In each area
SkinBioTherapeutics plans to exemplify its technology through human studies.
The Company's first product, AxisBiotix-Ps™, a food supplement to address
the symptoms of mild to moderate psoriasis.

The Company listed on AIM in April 2017 and is based in Newcastle, UK. For
more information, visit: www.skinbiotherapeutics.com
(http://www.skinbiotherapeutics.com) and www.axisbiotix.com
(http://www.axisbiotix.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGAGUUPCPUA